Clinical Trial

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Study acronym: PACIFICA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-01
notable Primary completion moved earlier: 2026-12-31 -> 2026-10-05 2026-05-01
minor Completion pushed: 2027-07-30 -> 2028-10-13 2026-05-01
Trial Details
NCT Number NCT03165734
Lead Sponsor Swedish Orphan Biovitrum
Collaborators: PSI CRO
Conditions Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Enrollment 407 participants
Start Date 2017-06-26
Primary Completion 2026-10-05 (estimated)
Study Completion 2028-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-30